Zyla Life Sciences Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-12-28: Form 8-K; Period of report 2017-12-27; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2017-12-20: Form 8-K; Period of report 2017-12-20; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2017-12-15: Form 8-K; Period of report 2017-12-15; Description 8.01 Other Events; Details 8.01.
- 2017-12-06: Form 8-K; Period of report 2017-12-06; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-12-28 | 8-K | 2017-12-27 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 As previously reported, on December 20, 2017, Egalet Corporation (the “Company”) entered into exchange agreements (the “Exchange Agreements”) with certain holders (the “Holders”) of the Company’s 5.50% convertible senior notes due 2020 (the “5.50% Notes”) pursuant to which the Holders agreed to exchange, in the aggregate, approximately $36.4 million of outstanding principal amount of the 5.50% Notes for, in the aggregate, (i) approximately $23.9 million of the Company’s new 6.50% convertible senior notes due 2024 (the “New Notes”), (ii) a warrant exercisable for 3.5 million shares of the Company’s common stock and (iii) payments, in cash, of all accrued but unpaid interest as of the closing on the 5.50% Notes exchanged in the transaction (the “Exchange”). 2.03 The information set forth under Item 1.01 of this Current Report is incorporated by reference herein. 3.02 The information set forth under Item 1.01 of this Current Report is incorporated by reference herein. | a17-29005_18k.htm |
| 2017-12-20 | 8-K | 2017-12-20 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On December 20, 2017, Egalet Corporation (the “Company”) entered into exchange agreements (the “Exchange Agreements”) with certain holders (the “Holders”) of the Company’s 5.50% convertible senior notes due 2020 (the “5.50% Notes”) pursuant to which the Holders have agreed to exchange, in the aggregate, approximately $36.4 million of outstanding principal amount of the 5.50% Notes for, in the aggregate, (i) approximately $23.9 million of the Company’s new 6.50% convertible senior notes due 2024 (the “New Notes”), (ii) a warrant exercisable for 3.5 million shares of the Company’s common stock and (iii) payments, in cash, of all accrued but unpaid interest as of the closing on the 5.50% Notes exchanged in the transaction (the “Exchange”). 8.01 On December 20, 2017, the Company issued a press release announcing that the Company had entered into the Exchange Agreements. | a17-28729_18k.htm |
| 2017-12-15 | 8-K | 2017-12-15 | 8.01 Other Events | 8.01 On December 15, 2017, Egalet Corporation issued a press release announcing that the U.S. Food and Drug Administration has issued tentative approval for its Supplemental New Drug Application for ARYMO ER that it submitted in February 2017. | a17-28541_18k.htm |
| 2017-12-06 | 8-K | 2017-12-06 | 8.01 Other Events | 8.01 Egalet Corporation (the “Company”) has been notified verbally by CVS Caremark (“Caremark”), a pharmacy benefits manager, that SPRIX Nasal Spray (“SPRIX”) will no longer be on its formulary for a portion of its commercial covered lives beginning January 1, 2018. | a17-28110_18k.htm |
| 2017-11-27 | 8-K | 2017-11-25 | 8.01 Other Events | 8.01 As Egalet Corporation (the “Company”) has disclosed previously, the Company is a party to an agreement with Apotex Corp. and Apotex Inc. (collectively, “Apotex”) that permits the potential launch of an authorized generic for SPRIX Nasal Spray in March 2018. | a17-27610_18k.htm |
| 2017-11-24 | 8-K | 2017-11-24 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. | a17-27525_18k.htm |
| 2017-11-08 | 8-K | 2017-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2017, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2017. | a17-26066_18k.htm |
| 2017-08-09 | 8-K | 2017-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2017, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2017. | a17-19909_18k.htm |
| 2017-07-11 | 8-K | 2017-07-06 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On July 6, 2017, Egalet Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), relating to an underwritten public offering of 16,666,667 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants to purchase 16,666,667 shares of Common Stock, at a combined public offering price of $1.80 per share and accompanying warrant. 8.01 On July 11, 2017, the Company issued a press release announcing the closing of the offering. | a17-15599_58k.htm |
| 2017-07-07 | 8-K/A | 2017-07-06 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 The information contained in Item 8.01 below regarding the Company’s cash, cash equivalents and marketable securities as of June 30, 2017 is incorporated herein by reference. 8.01 On July 6, 2017, the Company issued a press release announcing that the Company had priced an offering of its common stock and accompanying warrants. | a17-15599_48ka.htm |
| 2017-07-06 | 8-K | 2017-07-06 | 8.01 Other Events | 8.01 On July 6, 2017, the Company issued a press release announcing that the Company had priced an offering of its common stock and accompanying warrants. | a17-17039_18k.htm |
| 2017-07-05 | 8-K | 2017-07-05 | 8.01 Other Events | 8.01 On July 5, 2017, Egalet Corporation (the “Company”) issued a press release announcing its intention to offer and sell shares of its common stock and accompanying warrants in an underwritten public offering, subject to market conditions and other factors. | a17-15599_38k.htm |
| 2017-06-20 | 8-K | 2017-06-20 | 8.01 Other Events | 8.01 On June 20, 2017, Egalet Corporation (the “Company”) issued a press release announcing that it has received a Complete Response Letter from the U.S. Food and Drug Administration with respect to the Company’s prior approval supplement for 10 mg and 15 mg dosage strengths of OXAYDO® (oxycodone HCI, USP) tablets for oral use only—CII, a copy of which is filed herewith as Exhibit 99.1. | a17-15094_28k.htm |
| 2017-06-13 | 8-K | 2017-06-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 5.07 The 2017 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company was held on June 8, 2017. | a17-15094_18k.htm |
| 2017-06-06 | 8-K | 2017-06-06 | 8.01 Other Events | 8.01 On June 6, 2017, Egalet Corporation issued a press release announcing that one of the largest payers in the United States will provide coverage of ARYMO® ER (morphine sulfate) extended-release tablets for oral use — CII, a copy of which is filed herewith as Exhibit 99.1 and incorporated herein by reference. | a17-14832_18k.htm |
| 2017-05-10 | 8-K | 2017-05-10 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 10, 2017, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2017. 7.01 As disclosed above, on May 10, 2017, the Company will hold an Investor Day presentation during which it will provide information to investors about the Company. | a17-12765_18k.htm |
| 2017-04-10 | 8-K | 2017-04-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) Jean-François Formela, MD submitted his resignation from the Board of Directors (the “Board”) of Egalet Corporation (the “Company”) and all committees of the Board on which he served, effective upon receipt by the Secretary of the Company, which occurred on April 4, 2017. | a17-11113_18k.htm |
| 2017-03-29 | 8-K | 2017-03-29 | 8.01 Other Events | 8.01 On March 29, 2017, Egalet Corporation (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration does not object to the Company’s distribution of promotional materials and communications to healthcare professionals regarding the abuse-deterrent properties of ARYMO™ ER (morphine sulfate) extended-release tablets for oral use only —CII via the intranasal route, a copy of which is filed herewith as Exhibit 99.1. | a17-10087_18k.htm |
| 2017-03-09 | 8-K | 2017-03-09 | 2.02 Results of Operations and Financial Condition | 2.02 On March 9, 2017, Egalet Corporation issued a press release announcing its financial results for its fourth quarter and year ended December 31, 2016. | a17-7647_28k.htm |
| 2017-03-06 | 8-K | 2017-02-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a17-7647_18k.htm |
| 2017-01-18 | 8-K | 2017-01-18 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 On January 18, 2017, Egalet Corporation (the “Company”), completed the second and final closing (the “Second Closing”) of its offering (the “Offering”) of up to $80.0 million aggregate principal amount of its 13% senior secured notes (the “Notes”) issued pursuant to that certain indenture, dated August 31, 2016, by and among the Company, the Guarantors party thereto (the “Guarantors”) and U.S. Bank National Association, as trustee and collateral agent (the “Indenture”). 8.01 On January 18, 2017, the Company issued a press release announcing that the Company had completed the Second Closing and the sale of the ARYMO Royalty Rights. | a17-1510_38k.htm |
| 2017-01-09 | 8-K | 2017-01-09 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 As reported under Item 8.01 of this current report on Form 8-K, Egalet Corporation (the “Company”) issued a press release on January 9, 2017 announcing the United States Food and Drug Administration’s (“FDA”) approval of ARYMO™ ER. 8.01 On January 9, 2017, the Company announced that the FDA has approved ARYMO™ ER (morphine sulfate) extended-release tablets C-II for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. | a17-1510_28k.htm |
| 2017-01-09 | 8-K | 2017-01-09 | 7.01 Regulation FD Disclosure | 7.01 — Regulation FD Disclosure. | a17-1510_18k.htm |